Biofrontera Inc. is a specialty pharmaceutical company focused on the development and commercialization of dermatological products. Its primary aim is to address unmet needs in the treatment of skin diseases, with a particular emphasis on dermatology, represented by its flagship product, Ameluz. This prescription medication is used in photodynamic therapy to treat actinic keratosis and basal cell carcinoma, offering a non-invasive option for patients. Biofrontera Inc. also owns a range of other topical dermatology treatments and has made strategic partnerships to enhance its market presence. By driving innovation in skin health solutions, the company impacts the healthcare industry, notably benefiting dermatologists and their patients. Based in Woburn, Massachusetts, Biofrontera plays a significant role in dermatological therapeutics, striving to expand its product portfolio through continuous research and development. Its dedication to providing effective solutions for skin conditions aligns with broader trends in personalized and targeted healthcare, making it a notable player in the specialty pharma space.